HomeCompareVSYS vs JNJ

VSYS vs JNJ: Dividend Comparison 2026

VSYS yields 1000000.00% · JNJ yields 3.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 VSYS wins by $4.7683925249533696e+36M in total portfolio value
10 years
VSYS
VSYS
● Live price
1000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.7683925249533696e+36M
Annual income
$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00
Full VSYS calculator →
JNJ
Johnson & Johnson
● Live price
3.36%
Share price
$147.50
Annual div
$4.96
5Y div CAGR
5.8%
Payout ratio
55%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.0K
Annual income
$827.78
Full JNJ calculator →

Portfolio growth — VSYS vs JNJ

📍 VSYS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodVSYSJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, VSYS + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
VSYS pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

VSYS
Annual income on $10K today (after 15% tax)
$85,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$4,052,336,490,287,657,000,000,000,000,000,000,000,000,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$285.83/yr
After 10yr DRIP, annual income (after tax)
$703.61/yr
At 15% tax rate, VSYS beats the other by $4,052,336,490,287,657,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of VSYS + JNJ for your $10,000?

VSYS: 50%JNJ: 50%
100% JNJ50/50100% VSYS
Portfolio after 10yr
$2.3841962624766848e+36M
Annual income
$2,383,727,347,228,033,600,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.98%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

VSYS
No analyst data
Altman Z
-37.1
Piotroski
1/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
+55.1% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

VSYS buys
0
JNJ buys
0
No recent congressional trades found for VSYS or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricVSYSJNJ
Forward yield1000000.00%3.36%
Annual dividend / share$2.00$4.96
Payout ratio50%55%
1-year div growth0%4.2%
5-year div CAGR0%5.8%
Portfolio after 10y$4.7683925249533696e+36M$20.0K
Annual income after 10y$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00$827.78
Total dividends collected$4.7683311610149396e+36M$5.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: VSYS vs JNJ ($10,000, DRIP)

YearVSYS PortfolioVSYS Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$100,010,700$100,000,000.00$10,676$355.77+$100.00MVSYS
2$934,786,450,701$934,679,439,252.34$11,407$389.39+$934786.44MVSYS
3$8,165,787,108,578,292$8,164,786,887,076,042.00$12,198$426.53+$8165787108.57MVSYS
4$66,665,884,190,957,650,000$66,657,146,798,751,470,000.00$13,056$467.62+$66665884190957.63MVSYS
5$508,662,171,058,048,100,000,000$508,590,838,561,963,700,000,000.00$13,987$513.12+$508662171058048128.00MVSYS
6$3,627,235,248,428,489,700,000,000,000$3,626,690,979,905,457,600,000,000,000.00$14,998$563.56+$3.62723524842849e+21MVSYS
7$24,173,681,159,150,610,000,000,000,000,000$24,169,800,017,434,790,000,000,000,000,000.00$16,098$619.52+$2.417368115915061e+25MVSYS
8$150,567,402,861,454,640,000,000,000,000,000,000$150,541,537,022,614,370,000,000,000,000,000,000.00$17,295$681.69+$1.5056740286145463e+29MVSYS
9$876,477,100,281,847,600,000,000,000,000,000,000,000$876,315,993,160,785,800,000,000,000,000,000,000,000.00$18,599$750.82+$8.764771002818475e+32MVSYS
10$4,768,392,524,953,369,600,000,000,000,000,000,000,000,000$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00$20,022$827.78+$4.7683925249533696e+36MVSYS

VSYS vs JNJ: Complete Analysis 2026

VSYSStock

Viscount Systems, Inc., through its subsidiary, Viscount Communication and Control Systems Inc., designs, manufactures, and sells access control and security products in North America. It offers intercom and physical access control systems, and emergency communications systems for various applications, including condominium/apartment building access and intercom; residential intercom; gated home/community access and intercom; seniors/government housing access, tracking, and intercom; elevator access and tracking; garage or perimeter gate control; and emergency communications. The company's principal product is the Enterphone intercom and access control system, a patented building entry control system that uses a building's internal phone wiring to allow access control for tenants, and intercom and access control between visitors and tenants. It also manufactures electronic entry access panels that can operate using the Enterphone system or dial-up telephone company lines. In addition, the company offers Enterphone iQ, a solution based on its MESH technology; MESH, a software-based building management system; Freedom, an Internet technology platform; and Liberty, a derivation of the Freedom for the smaller sized system access control market. Viscount Systems, Inc. was founded in 1969 and is headquartered in Burnaby, Canada.

Full VSYS Calculator →

JNJHealthcare

Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.

Full JNJ Calculator →
📬

Get this VSYS vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

VSYS vs SCHDVSYS vs JEPIVSYS vs OVSYS vs KOVSYS vs MAINVSYS vs ABBVVSYS vs MRKVSYS vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.